Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $18.9100 (-1.77%) ($18.6000 - $18.9100) on Sun. Jan. 31, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.24% (three month average) | RSI | 23 | Latest Price | $18.9100(-1.77%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD declines -2.2% a day on average for past five trading days. | Weekly Trend | FOLD declines -8% a week on average for past two weeks. | Market Behavior | Normal for large cap. Normal for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) (0%) (0%) (0%) (0%) (0%) | Factors Impacting FOLD price | FOLD will decline at least -1.62% in a week (0% probabilities). (0%) (0%) (0%) (0%) (0%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.62% (StdDev 3.24%) | Hourly BBV | 0 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $6.6(-65.1%) | Resistance Level | $21.54 | 5 Day Moving Average | $19.45(-2.78%) | 10 Day Moving Average | $20.28(-6.76%) | 20 Day Moving Average | $21.54(-12.21%) | To recent high | -24.1% | To recent low | 6.7% | Market Cap | $N/A | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |